AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Companion Diagnostics Partnering Deal Trends, Players and Financials Directory 2019 - ResearchAndMarkets.com

May 21, 2019

DUBLIN--(BUSINESS WIRE)--May 21, 2019--

The “Global Companion Diagnostics Partnering 2014-2019: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.

The Global Companion Diagnostics Partnering 2014-2019 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the world’s leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Companion Diagnostics agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.

The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Companion Diagnostics partnering field; both the leading deal values and most active Companion Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 160 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Companion Diagnostics dealmaking.

A comprehensive series of appendices is provided organized by Companion Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Companion Diagnostics partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Companion Diagnostics technologies and products.

Key benefits

Key Topics Covered:

1. Introduction

2. Trends in Companion Diagnostics dealmaking

2.1. Introduction

2.2. Companion Diagnostics partnering over the years

2.3. Most active Companion Diagnostics dealmakers

2.4. Companion Diagnostics partnering by deal type

2.5. Companion Diagnostics partnering by therapy area

2.6. Deal terms for Companion Diagnostics partnering

2.6.1 Companion Diagnostics partnering headline values

2.6.2 Companion Diagnostics deal upfront payments

2.6.3 Companion Diagnostics deal milestone payments

2.6.4 Companion Diagnostics royalty rates

3. Leading Companion Diagnostics deals

3.1. Introduction

3.2. Top Companion Diagnostics deals by value

4. Most active Companion Diagnostics dealmakers

4.1. Introduction

4.2. Most active Companion Diagnostics dealmakers

4.3. Most active Companion Diagnostics partnering company profiles

5. Companion Diagnostics contracts dealmaking directory

5.1. Introduction

5.2. Companion Diagnostics contracts dealmaking directory

6. Companion Diagnostics dealmaking by technology type

7. Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 - Companion Diagnostics deals by company A-Z

Appendix 2 - Companion Diagnostics deals by stage of development

Appendix 3 - Companion Diagnostics deals by deal type

Appendix 4 - Companion Diagnostics deals by therapy area

Appendix 5 - Deal type definitions

Companies Mentioned

Sample list of companies, more included in the report

For more information about this report visit https://www.researchandmarkets.com/r/nruz7

View source version on businesswire.com:https://www.businesswire.com/news/home/20190521005613/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Diagnostics,In Vitro Diagnostics

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/21/2019 10:07 AM/DISC: 05/21/2019 10:07 AM

http://www.businesswire.com/news/home/20190521005613/en

All contents © copyright 2019 The Associated Press. All rights reserved.